Search
Bicycle Therapeutics PLC
BCYCAdd to Watchlist
3.740USD
+0.110+3.03%
Market hours 09/22, 11:41（ET）
188.41MMarket Cap
LossP/E TTM
About {index_name} Bicycle Therapeutics PLC Company
Bicycle Therapeutics plc is a United Kingdom-based clinical-stage biopharmaceutical company developing a class of medicines, referred to as Bicycle molecules, for diseases that are underserved by existing therapeutics. Bicycle molecules are fully synthetic short peptides constrained with small molecule scaffolds to form two loops that stabilize their structural geometry. The Company is evaluating zelenectide pevedotin, a Bicycle Toxin Conjugate (BTC) targeting Nectin-4, a well-validated tumor antigen; BT5528, a BTC targeting EphA2, a historically undruggable target, and BT7480, a Bicycle Tumor-Targeted Immune Cell Agonist (Bicycle TICA) targeting Nectin-4 and agonizing CD137, in Company-sponsored clinical trials. Additionally, the Company is developing Bicycle Radio Conjugates (BRC) for radiopharmaceutical use and, through various partnerships, is exploring the use of Bicycle technology to develop therapies for diseases beyond oncology.
Bicycle Therapeutics PLC Profile
Ticker SymbolBCYC
Company nameBicycle Therapeutics PLC
IPO dateMay 23, 2019
CEOLee (Kevin)
Number of employees305
Security typeDepository Receipt
Fiscal year-endMay 23
AddressBlocks A & B, Portway Building
CityCAMBRIDGE
Stock exchangeNASDAQ OMX - NASDAQ BASIC
CountryUnited Kingdom
Postal codeCB21 6GS
Phone11441223261503
Websitehttps://www.bicycletherapeutics.com/
Ticker SymbolBCYC
IPO dateMay 23, 2019
CEOLee (Kevin)
Company Executives of Bicycle Therapeutics PLC
Name
Name/Position
Position
Shareholding
Change
Dr. Kevin Lee, Ph.D.
Dr. Kevin Lee, Ph.D.
Chief Executive Officer, Executive Director
Chief Executive Officer, Executive Director
317.14K
+13.10%
Dr. Michael Skynner, Ph.D.
Dr. Michael Skynner, Ph.D.
Chief Technology Officer
Chief Technology Officer
69.97K
-4.22%
Mr. Alistair Milnes
Mr. Alistair Milnes
Chief Corporate Development Officer
Chief Corporate Development Officer
39.58K
+35.99%
Ms. Janice Bourque
Ms. Janice Bourque
Non-Executive Independent Director
Non-Executive Independent Director
25.38K
+27.83%
Dr. Alessandro Riva, M.D.
Dr. Alessandro Riva, M.D.
Non-Executive Independent Director
Non-Executive Independent Director
6.01K
--
Dr. Roger D. Dansey, M.D.
Dr. Roger D. Dansey, M.D.
Independent Director
Independent Director
758.00
--
Mr. Herve Hoppenot
Mr. Herve Hoppenot
Independent Director
Independent Director
758.00
-300.00%
Sir Gregory Winter
Sir Gregory Winter
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Dr. Jose Carlos Gutierrez-Ramos, Ph.D.
Dr. Jose Carlos Gutierrez-Ramos, Ph.D.
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Ms. Alethia R. Young, M.D.
Ms. Alethia R. Young, M.D.
Chief Financial Officer
Chief Financial Officer
--
--
View more
Name
Name/Position
Position
Shareholding
Change
Dr. Kevin Lee, Ph.D.
Dr. Kevin Lee, Ph.D.
Chief Executive Officer, Executive Director
Chief Executive Officer, Executive Director
317.14K
+13.10%
Dr. Michael Skynner, Ph.D.
Dr. Michael Skynner, Ph.D.
Chief Technology Officer
Chief Technology Officer
69.97K
-4.22%
Mr. Alistair Milnes
Mr. Alistair Milnes
Chief Corporate Development Officer
Chief Corporate Development Officer
39.58K
+35.99%
Ms. Janice Bourque
Ms. Janice Bourque
Non-Executive Independent Director
Non-Executive Independent Director
25.38K
+27.83%
Dr. Alessandro Riva, M.D.
Dr. Alessandro Riva, M.D.
Non-Executive Independent Director
Non-Executive Independent Director
6.01K
--
Dr. Roger D. Dansey, M.D.
Dr. Roger D. Dansey, M.D.
Independent Director
Independent Director
758.00
--
FAQs
Who are the top five shareholders of Bicycle Therapeutics PLC?
The top five shareholders of Bicycle Therapeutics PLC are: Dr. Kevin Lee, Ph.D.
How many institutions hold shares of Bicycle Therapeutics PLC (BCYC)?
As of 2026Q1, 250 institutions hold shares of Bicycle Therapeutics PLC, with a combined market value of approximately 33.87M, accounting for 67.23% of the total shares. Compared to 2025Q4, institutional shareholding has increased by -23140757.00.